DE3668186D1 - Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. - Google Patents

Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.

Info

Publication number
DE3668186D1
DE3668186D1 DE8686901978T DE3668186T DE3668186D1 DE 3668186 D1 DE3668186 D1 DE 3668186D1 DE 8686901978 T DE8686901978 T DE 8686901978T DE 3668186 T DE3668186 T DE 3668186T DE 3668186 D1 DE3668186 D1 DE 3668186D1
Authority
DE
Germany
Prior art keywords
eukaryontic
polypeptide
expressing
cell line
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686901978T
Other languages
English (en)
Inventor
Henry Kenten
Alan Boss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Group AG
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26289072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3668186(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858508442A external-priority patent/GB8508442D0/en
Priority claimed from GB858521815A external-priority patent/GB8521815D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of DE3668186D1 publication Critical patent/DE3668186D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
DE8686901978T 1985-04-01 1986-04-01 Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. Expired - Lifetime DE3668186D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858508442A GB8508442D0 (en) 1985-04-01 1985-04-01 Expression vector
GB858521815A GB8521815D0 (en) 1985-09-03 1985-09-03 Expression process
PCT/GB1986/000187 WO1986005807A1 (en) 1985-04-01 1986-04-01 Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same

Publications (1)

Publication Number Publication Date
DE3668186D1 true DE3668186D1 (de) 1990-02-15

Family

ID=26289072

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686901978T Expired - Lifetime DE3668186D1 (de) 1985-04-01 1986-04-01 Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.

Country Status (8)

Country Link
EP (1) EP0216846B2 (de)
JP (1) JP2532858B2 (de)
AU (1) AU584417B2 (de)
BG (1) BG60107A3 (de)
CA (1) CA1319120C (de)
DE (1) DE3668186D1 (de)
GB (1) GB2183662B (de)
WO (1) WO1986005807A1 (de)

Families Citing this family (376)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU582288B2 (en) * 1986-03-07 1989-03-16 Damon Biotech Inc. Vector and method for achieving high level expression in eukaryotic cells
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
JP2585532B2 (ja) * 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法
EP0272315A1 (de) * 1986-06-26 1988-06-29 Damon Biotech, Inc. Rekombinante zubereitung des plasminogenaktivators von menschlichem gewebe
EP0255320A3 (de) * 1986-07-28 1989-09-06 Genzyme Corporation Herstellung von Proteinen in Myelomazellen
CA1297435C (en) * 1986-09-12 1992-03-17 Stephen D. Gillies Messenger rna stabilization in animal cells
AU2263288A (en) * 1987-07-16 1989-02-13 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5747308A (en) * 1989-10-25 1998-05-05 Celltech Therapeutics Limited Recombinant DNA method
GB9209993D0 (en) 1992-05-08 1992-06-24 Munn Edward A Vaccines
DE69324375T2 (de) * 1992-11-28 1999-08-26 Chemo Sero Therapeut Res Inst Herstellungsprozess von fremdprotein
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
HU229566B1 (en) 1998-12-23 2014-02-28 Pfizer Human monoclonal antibodies to ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
AR022236A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2338512A1 (de) 2000-11-28 2011-06-29 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ATE464322T1 (de) 2001-01-05 2010-04-15 Pfizer Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
NZ579419A (en) 2002-02-07 2011-02-25 Dyax Corp Albumin-fused kunitz domain peptides
US20030180819A1 (en) 2002-03-01 2003-09-25 Carney Walter P. Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
DE60329020D1 (de) 2002-03-01 2009-10-08 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
SI1503794T1 (sl) 2002-04-12 2012-09-28 Medarex Inc Postopek zdravljenja z uporabo ctla-4 antiteles
EP1499352A4 (de) 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
EP2316922B1 (de) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
DE60322744D1 (de) 2002-12-30 2008-09-18 Biogen Idec Inc Kim-1-antagonisten und verwendung zur immunsystemmodulation
ES2457538T3 (es) 2003-02-20 2014-04-28 Seattle Genetics, Inc. Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2697327T3 (es) 2003-11-06 2019-01-23 Seattle Genetics Inc Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
DK1711528T3 (da) 2003-12-23 2012-08-20 Genentech Inc Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
EP1726647B1 (de) 2004-03-19 2015-01-07 GenomIdea, Inc. Gen zur förderung des wachstums von gefässendothelzellen
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
BRPI0513200A (pt) 2004-07-16 2008-04-29 Pfizer Prod Inc uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
PL1781321T3 (pl) 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1868647A4 (de) 2005-03-24 2009-04-01 Millennium Pharm Inc Ov064-bindende antikörper und verfahren zu ihrer verwendung
EP1871418B1 (de) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
MX2007013217A (es) 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008604A2 (en) 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
WO2007019541A2 (en) 2005-08-08 2007-02-15 Onconon, Llc. Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
KR101536506B1 (ko) 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
EP3299027A1 (de) 2005-11-04 2018-03-28 Genentech, Inc. Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP1965827B1 (de) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
ES2550099T3 (es) 2006-01-27 2015-11-04 Biogen Ma Inc. Antagonistas del receptor Nogo
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2007118214A2 (en) 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2405270B1 (de) 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
JP5235881B2 (ja) 2006-08-11 2013-07-10 シーエスエル、リミテッド 肺疾患病態の処理
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
MX2009006466A (es) 2006-12-13 2009-06-26 Schering Corp Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
LT2436696T (lt) 2007-01-05 2017-08-25 University Of Zurich Anti-beta-amiloido antikūnas ir jo panaudojimas
NZ577976A (en) 2007-01-09 2011-12-22 Biogen Idec Inc Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
AU2008214337B2 (en) 2007-02-02 2012-07-05 Biogen Ma Inc. Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
EP2112930B1 (de) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
EP2121745A2 (de) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Proteine
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
TWI570135B (zh) 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗－ｃｄ４抗體
EP2703011A3 (de) 2007-05-07 2014-03-26 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
AU2008255027B2 (en) 2007-05-14 2013-10-03 Astrazeneca Ab Methods of reducing eosinophil levels
RU2015147300A (ru) 2007-08-29 2019-01-11 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
EP2215113B1 (de) 2007-10-26 2015-02-25 CSL Limited Cytokin-muteine
CA2703705A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
EP3002298B1 (de) 2007-11-21 2019-08-28 Oregon Health & Science University Anti-faktor xi monoklonale antikörper und verfahren zur verwendung davon
CN103772502B (zh) 2007-12-07 2017-03-29 津莫吉尼蒂克斯公司 抗人il‑21单克隆抗体
EP2245049B1 (de) 2008-01-10 2015-05-20 Research Development Foundation Impfstoffe und diagnostika für ehrlichiosen
CA2711736A1 (en) 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
EP2250279B1 (de) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1-antikörper mit reduzierter fc-ligandenaffinität
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
EP2358392B1 (de) 2008-11-12 2019-01-09 MedImmune, LLC Antikörper-formulierung
CN102300874B (zh) 2008-12-08 2015-08-05 卡姆普根有限公司 Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US20120058131A1 (en) 2009-01-21 2012-03-08 Oxford Biotherapeutics Ltd Pta089 protein
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2411412B1 (de) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanisierte antikörper gegen licht und anwendungen davon
MX2011011718A (es) 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
ES2629167T3 (es) 2009-07-20 2017-08-07 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
AR077594A1 (es) 2009-07-31 2011-09-07 Organon Nv Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
WO2011032204A1 (en) 2009-09-15 2011-03-24 Csl Limited Treatment of neurological conditions
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
EA201792376A3 (ru) 2009-10-23 2018-08-31 Милленниум Фармасьютикалз, Инк. Молекулы анти-gcc антитела и соответствующие композиции и способы
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
EP2325322A1 (de) 2009-11-23 2011-05-25 4-Antibody AG Retrovirusvektorpartikel und Verfahren zu deren Erzeugung und Verwendung
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
BR112012026403B1 (pt) 2010-04-16 2022-10-04 Biogen Ma Inc Molécula de anticorpo recombinante ou um fragmento de ligação a ?4 da mesma e seu uso
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
RS59769B1 (sr) 2010-06-09 2020-02-28 Genmab As Antitela protiv humanog cd38
EP2582728B1 (de) 2010-06-15 2017-08-23 Genmab A/S Menschliche antikörper-arzneimittelkonjugate gegen den gewebefaktor
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
KR20140018837A (ko) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 노텀 단백질 조절 인자 및 사용 방법
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
TWI585106B (zh) 2010-12-08 2017-06-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170807A2 (en) 2011-06-10 2012-12-13 Medimmune, Llc Anti-pseudomonas psl binding molecules and uses thereof
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
WO2013001369A2 (en) 2011-06-28 2013-01-03 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CA2848074A1 (en) 2011-09-09 2013-03-14 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
ES2899956T3 (es) 2011-11-04 2022-03-15 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013078118A1 (en) 2011-11-21 2013-05-30 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
EP2794653B1 (de) 2011-12-23 2019-03-13 Pfizer Inc Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
CA2864092C (en) 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
EP2817338B1 (de) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3-modulatoren und verwendungsverfahren
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2841101B1 (de) 2012-04-26 2019-08-07 University Of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013173364A2 (en) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
AU2013329421A1 (en) 2012-10-09 2015-04-30 Biogen Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
EP2906683B1 (de) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Säugerzellkulturverfahren zur proteinproduktion
US10233229B2 (en) 2012-12-07 2019-03-19 Pfizer Inc. Engineered monomeric antibody fragments
WO2014100600A2 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Human anti-tau antibodies
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA2896824A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
AU2014218730B2 (en) 2013-02-22 2018-12-13 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
EP2970909A4 (de) 2013-03-15 2017-02-15 The University of Chicago Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
EP2981821B2 (de) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunhistochemischer test zum nachweis der expression des liganden 1 für programmierten zelltod (pd-l1) in tumorgewebe
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
JP2016521744A (ja) 2013-06-13 2016-07-25 ファスト フォワード ファーマスーティカルズ ベー．フェー． 追加化合物が胆汁酸、胆汁酸誘導体、ｔｇｒ５受容体作動物質、ｆｘｒ作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのｃｄ４０シグナル伝達阻害物質および追加化合物
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CA2922478C (en) 2013-08-26 2020-09-29 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
CA2922547C (en) 2013-08-28 2020-03-10 Stemcentrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
EP3143043B1 (de) 2014-05-16 2022-12-14 Pfizer Inc. Bispezifische antikörper mit modifizierten ch1-cl interaktionen
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
NZ764877A (en) 2014-06-04 2023-12-22 Biontech Res And Development Inc Human monoclonal antibodies to ganglioside gd2
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MY184288A (en) 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
AU2015316522B2 (en) 2014-09-16 2021-01-21 Symphogen A/S Anti-met antibodies and compositions
EP3224595A4 (de) * 2014-09-24 2018-06-13 Good Start Genetics, Inc. Prozesssteuerung für erhöhte robustheit von genetischen assays
KR20230104759A (ko) 2014-09-30 2023-07-10 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
PT3240801T (pt) 2014-12-31 2021-02-18 Checkmate Pharmaceuticals Inc Imunoterapia antitumoral combinada
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
KR102261618B1 (ko) 2015-03-31 2021-06-04 메디뮨 리미티드 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
CN113861294B (zh) 2015-04-02 2024-03-08 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
HUE054435T2 (hu) 2015-04-06 2021-09-28 Subdomain Llc De novo kötõdomént tartalmazó polipeptidek és alkalmazásaik
TWI820377B (zh) 2015-05-07 2023-11-01 美商艾吉納斯公司 抗ｏｘ４０抗體及其使用方法
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
EP3377526A1 (de) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Pd1/ctla4-bindemittel
EP3377527A1 (de) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Ctla4-bindemittel
JP2019507582A (ja) 2015-12-04 2019-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法用のｓｌｃ４５ａ２ペプチド
AU2016371639A1 (en) 2015-12-16 2018-06-28 Merck Sharp & Dohme Llc Anti-LAG3 antibodies and antigen-binding fragments
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
MX2018012076A (es) 2016-04-12 2019-02-20 Symphogen As Composiciones y anticuerpos anti proteina 3 que contiene inmunoglobulina de linfocitos t y el dominio de mucina (tim-3).
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
EP3481864A1 (de) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
CN109862911A (zh) 2016-07-13 2019-06-07 比奥根Ma公司 Lingo-1拮抗剂的剂量方案和用于治疗脱髓鞘病症的用途
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
BR112019011651A2 (pt) 2016-12-07 2020-01-07 Agenus Inc. Anticorpos anti-cttla-4 e métodos de uso dos mesmos
MA49042A (fr) 2017-04-05 2020-02-12 Symphogen As Polythérapies ciblant pd-1, tim-3 et lag-3
KR20190140454A (ko) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
EP3612560A1 (de) 2017-04-21 2020-02-26 Staten Biotechnology B.V. Anti-apoc3-antikörper und verfahren zur verwendung davon
KR102637960B1 (ko) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JP7222915B2 (ja) 2017-05-02 2023-02-15 イミュノミック セラピューティックス， インコーポレイテッド 癌抗原を含む改善されたｌａｍｐ構築物
SG11201909466RA (en) 2017-05-05 2019-11-28 Vaccinex Inc Human anti-semaphorin 4d antibody
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3652211A1 (de) 2017-07-14 2020-05-20 Pfizer Inc. Antikörper gegen madcam
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
BR112020008514A2 (pt) 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
BR112020009136A2 (pt) 2017-11-14 2020-10-13 Arcellx, Inc. polipeptídeos que contêm domínio d e usos dos mesmos
JP7356435B2 (ja) 2017-11-14 2023-10-04 アーセルクス インコーポレイテッド 多機能性免疫細胞療法
PT110526B (pt) 2018-01-26 2021-02-04 Univ Nova De Lisboa Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN111971308A (zh) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-h4抗体及其使用方法
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
KR20210018316A (ko) 2018-05-30 2021-02-17 애브비 스템센트알엑스 엘엘씨 항-sez6 항체 약물 접합체 및 사용 방법
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
RU2706298C1 (ru) 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" НУКЛЕАЗА PaCas9
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
TW202034958A (zh) 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
US11617798B2 (en) 2019-02-05 2023-04-04 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
KR20210126078A (ko) 2019-02-13 2021-10-19 더 브리검 앤드 우먼즈 하스피털, 인크. 항-말초 림프절 어드레신 항체 및 그의 용도
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
AU2020300002A1 (en) 2019-07-01 2022-02-24 Tonix Pharma Limited Anti-CD154 antibodies and uses thereof
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
CA3145347A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
BR112022003740A2 (pt) 2019-08-30 2022-05-31 Agenus Inc Anticorpos anti-cd96 e métodos de uso dos mesmos
WO2021044005A1 (en) 2019-09-06 2021-03-11 Symphogen A/S Anti-cd73 antibodies
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
EP4038101A2 (de) 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1-antikörper und antikörperwirkstoffkonjugate
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
BR112022006534A2 (pt) 2019-10-24 2022-07-05 Novago Therapeutics Ag Anticorpos anti-nogo-a
KR20220121792A (ko) 2019-11-04 2022-09-01 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트 및 hiv 감염 치료를 위한 이의 용도
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
WO2021090272A1 (en) 2019-11-07 2021-05-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CN114829397A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体
WO2021123091A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US20230220074A1 (en) 2020-02-18 2023-07-13 Alector Llc Pilra antibodies and methods of use thereof
KR20230017207A (ko) 2020-04-30 2023-02-03 사이로파 비.브이. 항-cd103 항체
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
WO2021233834A1 (en) 2020-05-17 2021-11-25 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
US20230242624A1 (en) 2020-06-02 2023-08-03 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CN116322787A (zh) 2020-06-29 2023-06-23 展马博联合股份有限公司 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
IL299757A (en) 2020-07-20 2023-03-01 Astrazeneca Uk Ltd SARS-COV-2 proteins, antibodies against SARS-COV-2, and methods of using them
EP4185322A2 (de) 2020-07-24 2023-05-31 Amgen Inc. Immunogene aus sars-cov2-spike-protein
IL300176A (en) 2020-08-04 2023-03-01 Seagen Inc Anti-CD228 antibodies and antibody-drug conjugates
CN116761821A (zh) 2020-08-18 2023-09-15 赛福伦有限责任公司 抗par-2抗体及其使用方法
JP2023540082A (ja) 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体
WO2022081779A1 (en) 2020-10-13 2022-04-21 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
US20230391829A1 (en) 2020-10-13 2023-12-07 Avitide LLC Aav8 affinity agents
US20230391879A1 (en) 2020-10-15 2023-12-07 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
CA3201893A1 (en) 2020-12-11 2022-06-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising sfrp2 antagonists
EP4271708A1 (de) 2020-12-29 2023-11-08 Neurimmune AG Menschliche anti-tau-antikörper
EP4294542A1 (de) 2021-02-19 2023-12-27 Avitide LLC Aav2-affinitätswirkstoffe
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
CA3227816A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CA3234609A1 (en) 2021-10-15 2023-04-20 Leila M. BOUSTANY Activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
US20230174995A1 (en) 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2023180533A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023242361A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn binding molecules and methods of use
GB2619976A (en) 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines

Also Published As

Publication number Publication date
EP0216846B2 (de) 1995-04-26
GB8628482D0 (en) 1987-01-07
WO1986005807A1 (en) 1986-10-09
EP0216846A1 (de) 1987-04-08
AU5666586A (en) 1986-10-23
CA1319120C (en) 1993-06-15
GB2183662A (en) 1987-06-10
EP0216846B1 (de) 1990-01-10
GB2183662B (en) 1989-01-25
AU584417B2 (en) 1989-05-25
JPS62502377A (ja) 1987-09-17
BG60107A3 (en) 1993-10-15
JP2532858B2 (ja) 1996-09-11

Similar Documents

Publication Publication Date Title
DE3668186D1 (de) Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
DE3675567D1 (de) Verstaerkte kautschukmischungen, verfahren zu ihrer herstellung und ihre verwendung.
DE3582576D1 (de) Dithioketo-pyrrolo-pyrrole, verfahren zu deren herstellung und verwendung.
DE3280174D1 (de) Desoxyribonucleinsaeuren, rekombinante desoxyribonucleinsaeuren, sie enthaltende wirte, polypeptide und verfahren zu ihrer herstellung.
DK100985D0 (da) Dna, der koder for human tumornecrosefaktor, samt humant tumornecrosefaktor-polypeptid og fremgangsmaader til fremstilling heraf
EP0190254A4 (de) Kloniertes gen, verfahren zu dessen herstellung und seine verwendung.
DE3587732T2 (de) Verfahren zum Vorbereiten von numerischen Steuerungsdaten für das Einsetzen von Bauelementen.
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE3682928D1 (de) Verfahren zum polymerisieren von aethylen.
DE3581231D1 (de) Verfahren zur expression von polypeptiden.
ES513287A0 (es) "un metodo con su aparato correspondiente, para la limpieza de electrodos".
DE3677740D1 (de) 2-iod-perfluor-2-methylalkane, verfahren zu deren herstellung und deren verwendung.
DE3677812D1 (de) Polyhydroxypolyether, verfahren zu ihrer herstellung und ihre verwendung.
DE3670500D1 (de) Polycyanoarylether und verfahren zu ihrer herstellung.
DE3688311D1 (de) Verfahren zum zuechten von rekombinanten zellen.
DE3682551D1 (de) Placenta-kollagenpraeparate, verfahren zu ihrer extraktion und ihre verwendung.
DE3671231D1 (de) Cysteinreiche, gamma-glutaminsaeure-einheiten aufweisende peptide, verfahren zu deren herstellung und ihre verwendung.
DE3586940D1 (de) Polypeptid und dessen verfahren zur herstellung.
DE3675701D1 (de) Polyoxyalkylen-carbazol-addukt, sowie verfahren zu dessen herstellung.
ATE49423T1 (de) Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
DE3483977D1 (de) Verfahren zur expression eines fremden gens.
DE3574699D1 (de) Monocyclische bis-oxethylsulfonyl-aniline und verfahren zu ihrer herstellung.
ZM9578A1 (en) Method and means for microbial polypeptide expression,synthetic dna and process therefor
DE3686148T2 (de) Lymphotoxin-gen, verfahren zu dessen herstellung und lymphotoxin.
DE3784218D1 (de) Neue thiochinacridone und isothiochinacridone, verfahren zu deren herstellung und verwendung.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: ALUSUISSE HOLDINGS A.G., NEUHAUSEN AM RHEINFALL, C

8327 Change in the person/name/address of the patent owner

Owner name: LONZA GROUP AG, ZUERICH, CH